2024
Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data
Torgersen J, Mezochow A, Newcomb C, Carbonari D, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Re V. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data. JAMA Internal Medicine 2024, 184: 943-952. PMID: 38913369, PMCID: PMC11197444, DOI: 10.1001/jamainternmed.2024.1836.Peer-Reviewed Original ResearchIncidence rateUS Department of Veterans AffairsMedication initiationDepartment of Veterans AffairsInitiation of medicationVeterans AffairsMain OutcomesPotential of medicationsOutpatient settingDischarge diagnosisCohort studyDay of admissionCase reportReal World DataReport countsMedicationMedical cohortSevere acute liver injuryUS DepartmentFollow-upAcute liver injuryHospitalCohortHepatotoxic medicationsIncidence
2022
Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY
Green A, Curtis H, Hulme W, Williamson E, McDonald H, Bhaskaran K, Rentsch C, Schultze A, MacKenna B, Mahalingasivam V, Tomlinson L, Walker A, Fisher L, Massey J, Andrews C, Hopcroft L, Morton C, Croker R, Morley J, Mehrkar A, Bacon S, Evans D, Inglesby P, Hickman G, Ward T, Davy S, Mathur R, Tazare J, Eggo R, Wing K, Wong A, Forbes H, Bates C, Cockburn J, Parry J, Hester F, Harper S, Douglas I, Evans S, Smeeth L, Goldacre B. Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY. BMC Medicine 2022, 20: 243. PMID: 35791013, PMCID: PMC9255436, DOI: 10.1186/s12916-022-02422-0.Peer-Reviewed Original ResearchConceptsPositive SARS-CoV-2 testSARS-CoV-2 testBreakthrough COVID-19Vaccine breakthroughBreakthrough casesCohort studyIncidence rateCOVID-19COVID-19-related hospital admissionsCOVID-19-related deathsVaccine breakthrough casesRetrospective cohort studyChronic kidney diseaseCritical care admissionSARS-CoV-2 variantsDeath registry dataCorresponding incidence ratesRoutine clinical dataHigh rateMedian followVaccine waningCare admissionHospital admissionSecond vaccinationSecondary care
2020
Risk of 16 cancers across the full glycemic spectrum: a population-based cohort study using the UK Biobank
Rentsch CT, Farmer RE, Eastwood SV, Mathur R, Garfield V, Farmaki AE, Bhaskaran K, Chaturvedi N, Smeeth L. Risk of 16 cancers across the full glycemic spectrum: a population-based cohort study using the UK Biobank. BMJ Open Diabetes Research & Care 2020, 8: e001600. PMID: 32859587, PMCID: PMC7454242, DOI: 10.1136/bmjdrc-2020-001600.Peer-Reviewed Original ResearchConceptsCancer riskGlycemic spectrumIncident cancerPancreatic cancerBreast cancerPopulation-based cohort studyAge-standardized incidence ratesCox proportional hazards modelPostmenopausal breast cancerPremenopausal breast cancerHistory of cancerIndependent positive associationProportional hazards modelUK cancer registriesUK BiobankEdition diagnostic codesBaseline HbA1cDiabetes medicationsMultivariable adjustmentCohort studyCancer RegistryRisk factorsDiagnostic codesIncidence rateInverse associationSafety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder
Rentsch CT, Morford KL, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2020, 44: 1807-1815. PMID: 32628784, PMCID: PMC7540277, DOI: 10.1111/acer.14408.Peer-Reviewed Original ResearchConceptsAlcohol use disorderMental statusRelative riskGabapentin exposureUse disordersICD-9 diagnostic codesAdverse neurologic effectsPotential medication interactionsAltered mental statusIncidence of fallsClear dose-response relationshipLarge clinical cohortDose-response relationshipRace/ethnicityUnexposed patientsHepatitis CAdverse eventsMedication interactionsExcess riskNeurologic effectsUS veteransDiagnostic codesIncidence rateClinical cohortHigh risk